Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211942 | 1.00 | NPC1 (0.59) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL24071023 | 0.87 | NPC1 (0.61) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL25949199 | 0.86 | RXFP1 (0.65) | NPC1RAB9AALDH1A1 | |
| SCHEMBL2105853 | 0.83 | NPC1 (0.67) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL25337572 | 0.83 | NPC1 (0.55) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL24071081 | 0.82 | MAPT (0.67) | NPC1RAB9AP2RX1MAPTTSHR | |
| SCHEMBL25949183 | 0.79 | MEN1 (0.62) | NPC1RAB9AALDH1A1MAPTHTT | |
| SCHEMBL12368157 | 0.79 | NPC1 (0.65) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL5498009 | 0.79 | RAB9A (0.71) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL95289 | 0.78 | NPC1 (0.70) | NPC1RAB9AP2RX1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | NPC1 2973/4885RAB9A 2278/4885P2RX1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.